Genmab — Januar 2020
-
EARLY Results of TOTAL Therapy 7 (TT7): High Response Rates of NEWLY Diagnosed High Risk Myeloma to Daratumumab. In TT7, we introduced Dara during all phases of therapy, including immune consolidation early post ASCT, to improve responses rate and PFS in HRMM.
-
The 1-yr cumulative incidence estimates for reaching VGPR and PR were 87 and 83%, respectively. A CR or sCR was achieved in 68 and 46%. The early results of TT7 point to increased response rates of HRMM to a dara-based TT regimen with especially higher rates of CR and sCR
-
if you are still interested in Ofatumumab in CLL - https://www.nature.com/articles/s41408-019-0260-2
-
Årets indtil videre dårligste c25 aktie og at vi falder så meget i dag efter Morgan løfter kursmålet til 1700 er lidt uforståeligt. At der er tvivl om de 3 B nåes -
som er sikre på den lange bane finder jeg det mærkeligt at vi ligger næsten 5% nede i år
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind